C3 and C9 complement fragment deposition in vitro
| Patient . | Percentage C3-positive cells (MFI) . | Percentage C9-positive cells (MFI) . | Lysis (%) . | ||
|---|---|---|---|---|---|
| R . | R + HS . | R . | R + HS . | ||
| PLL 2 | 25 (23) | 88 (294) | 1 | 3 (46) | 11 |
| PLL 4 | 2 (108) | 86 (875) | 1 | 43 (21) | 58 |
| CLL 32 | 23 (95) | 81 (599) | 0 | 50 (20) | 42 |
| MCL 1 | 22 (127) | 83 (799) | 0 | 59 (17) | 54 |
| Patient . | Percentage C3-positive cells (MFI) . | Percentage C9-positive cells (MFI) . | Lysis (%) . | ||
|---|---|---|---|---|---|
| R . | R + HS . | R . | R + HS . | ||
| PLL 2 | 25 (23) | 88 (294) | 1 | 3 (46) | 11 |
| PLL 4 | 2 (108) | 86 (875) | 1 | 43 (21) | 58 |
| CLL 32 | 23 (95) | 81 (599) | 0 | 50 (20) | 42 |
| MCL 1 | 22 (127) | 83 (799) | 0 | 59 (17) | 54 |
PBMCs from the indicated patients were incubated with rituximab in the presence or absence of 25% human serum for 3 hours, washed, and stained with antibodies specific for the indicated complement fragments by indirect immunofluorescence. MFI indicates mean fluorescence intensity; R, rituximab only; R + HS, rituximab and human serum; PLL, prolymphocytic leukemia; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma.